Home Cart Sign in  
Chemical Structure| 320-67-2 Chemical Structure| 320-67-2

Structure of 5-Azacytidine
CAS No.: 320-67-2

Chemical Structure| 320-67-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

5-Azacytidine is a nucleoside analogue of cytidine that specifically inhibits DNA methylation by trapping DNA methyltransferases.

Synonyms: Azacitidine; 5-AzaC; WR 183027

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Boyao Zhang ; George-Eugen Maftei ; Bartosz Bartmanski ; Michael Zimmermann ;

Abstract: Organic carcinogens, in particular DNA-reactive compounds, contribute to the irreversible initiation step of tumorigenesis through introduction of genomic instability. Although carcinogen bioactivation and detoxification by human enzymes has been extensively studied, carcinogen biotransformation by human-associated bacteria, the microbiota, has not yet been systematically investigated. We tested the biotransformation of 68 mutagenic carcinogens by 34 bacterial species representative for the upper and lower human gastrointestinal tract and found that the majority (41) of the tested carcinogens undergo bacterial biotransformation. To assess the functional consequences of microbial carcinogen metabolism, we developed a pipeline to couple gut bacterial carcinogen biotransformation assays with Ames mutagenicity testing and liver biotransformation experiments. This revealed a bidirectional crosstalk between gut microbiota and host carcinogen metabolism, which we validated in gnotobiotic mouse models. Overall, the systematic assessment of gut microbiota carcinogen biotransformation and its interplay with host metabolism highlights the gut microbiome as an important modulator of exposome-induced tumorigenesis.

Alternative Products

Product Details of 5-Azacytidine

CAS No. :320-67-2
Formula : C8H12N4O5
M.W : 244.20
SMILES Code : OC[C@@H]1[C@H]([C@H]([C@H](N2C(N=C(N=C2)N)=O)O1)O)O
Synonyms :
Azacitidine; 5-AzaC; WR 183027
MDL No. :MFCD00006539
InChI Key :NMUSYJAQQFHJEW-KVTDHHQDSA-N
Pubchem ID :9444

Safety of 5-Azacytidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335-H351-H361
Precautionary Statements:P261-P305+P351+P338

Related Pathways of 5-Azacytidine

epigenetics
DNA

Isoform Comparison

Biological Activity

Target
  • DNA Methyltransferase

In Vitro:

Cell Line
Concentration Treated Time Description References
LLC1 cells 100nM 72 h To evaluate the effect of 5-Azacytidine on the proliferation of LLC1 cells, results showed that 100nM 5-Azacytidine had limited effect on cell proliferation. PMC8765085
HNM007 cells 100nM 72 h To evaluate the effect of 5-Azacytidine on the proliferation of HNM007 cells, results showed that 100nM 5-Azacytidine had limited effect on cell proliferation. PMC8765085
4T1 cells 100nM 72 h To evaluate the effect of 5-Azacytidine on the proliferation of 4T1 cells, results showed that 100nM 5-Azacytidine had limited effect on cell proliferation. PMC8765085
Primary murine kidney fibroblasts 100 or 150 μg/ml 1 or 2 days 5′-Azacytidine effectively de-methylated Rasal1 and rescued endogenous Rasal1 expression, normalizing the proliferative activity of fibrotic renal fibroblasts. PMC4337426
ERC cells 10 µM 24 h Induce differentiation of ERC cells into cardiomyocytes PMC2212625
human cardiac stem cells (hCSCs) 10 μM 9 days 5-Azacytidine inhibits DNA methylation, leading to decreased levels of DNMT3a and SIRT1, thereby affecting epigenetic modifications and autophagy PMC9188476
THP-1 cells 10 μM 24 h 5-Azacytidine effectively blocked the LPS-induced upregulation of DNMT3b, increased PPARγ expression, and reduced IL-1β expression. PMC11600256
NSCLC cell lines 500 nM 24 h daily for 11 days To investigate the effect of 5-Azacytidine in combination with HDAC inhibitors (e.g., ITF-2357) on the proliferation of NSCLC cells, results showed that the combination significantly inhibited cell proliferation. PMC5808406
A549 and H460 cells 500 nM 11 days To investigate the inhibitory effect of 5-Azacytidine in combination with ITF-2357 on the proliferation of A549 and H460 cells, results showed that the combination significantly inhibited cell proliferation. PMC5808406
medaka fibroblast cells 2 μM 5 days 5-Azacytidine was used to reactivate the expression of Teratorn genes. The results showed that 5-azacytidine treatment moderately increased the expression of some Teratorn genes, although the expression level of most genes remained low. PMC5601938
OCI-LY1 0.3 µM 3 days 5-Azacytidine enhanced the sensitivity of OCI-LY1 cells to cisplatin, but the effect was less significant compared to other cell lines. PMC10155448
SU-DHL2 0.3 µM 3 days 5-Azacytidine significantly enhanced the sensitivity of SU-DHL2 cells to cisplatin, reducing the IC50 value below the clinically achievable concentration. PMC10155448
SU-DHL8 0.3 µM 3 days 5-Azacytidine significantly enhanced the sensitivity of SU-DHL8 cells to cisplatin, reducing the IC50 value below the clinically achievable concentration. PMC10155448
T-HEp3 cells 5 nM 48 hours AZA+atRA reprogramming inhibited the growth of T-HEp3 cells PMC10592471
4T1 cells 5 nM 48 hours AZA+atRA reprogramming inhibited the growth of 4T1 cells PMC10592471

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Balb/c mice Intraperitoneal injection 5 mg/kg Following the specified schedule Inhibit DNMT1 to reduce CTX-induced myeloid cell expansion PMC7868404
mice LLC and HNM007 pulmonary metastasis models subcutaneously injected 0.5mg/kg daily for 14 days To evaluate the effect of 5-Azacytidine on pulmonary metastasis models, results showed that low dose 5-Azacytidine inhibited the accumulation of MDSCs in the lung and prolonged disease-free and overall survival. PMC8765085
Mice Unilateral ureteral obstruction (UUO) model Intraperitoneal injection 10 mg/kg Every other day until the indicated time points 5′-Azacytidine significantly ameliorated renal fibrosis in mice, reduced fibrotic areas and fibroblast accumulation, and restored Rasal1 expression. PMC4337426
mice LPS-induced acute lung injury model intraperitoneal injection 1 mg/kg once daily for 3 days 5-Azacytidine significantly alleviated LPS-induced lung tissue damage and alveolar-capillary barrier injury, and reduced inflammatory cytokine levels in BAL fluid. PMC11600256
Mice NOD/SCID mouse model Intraperitoneal injection 0.5 mg/kg Every 14 days for a total of 28 days To investigate the anti-tumor effect of 5-Azacytidine in combination with ITF-2357 in a NSCLC mouse model, results showed that the combination significantly reduced tumor volume and weight. PMC5808406
Nude mice OCI-LY1 and SU-DHL2 xenograft models Intraperitoneal injection 0.5 mg/kg Once daily for 5 consecutive days 5-Azacytidine significantly enhanced the cytotoxic effect of cisplatin in the SU-DHL8 xenograft model, but the effect was not significant in the OCI-LY1 model. PMC10155448

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02985190 MDS|Systemic Autoimmune Diseas... More >>es Less << PHASE2 COMPLETED 2022-08-30 CHU Amiens, Amiens cedex 01, 8... More >>0054, France|CHU d'Angers, Angers cedex 9, 49933, France|Centre hospitalier Victor Dupouy, Argenteuil, 95107, France|CH Henri Duffaut d'Avignon, Avignon, 84000, France|Centre hospitalier de la C?te Basque, Bayonne cedex, 64109, France|H?pital Nord Franche-Comté, Belfort, 90015, France|H?pital Avicenne, Bobigny, 93009, France|Centre Hospitalier de Boulogne Sur Mer, Boulogne-sur-Mer, 62321, France|CHRU de Brest - H?pital Morvan, Brest, 29609, France|CHU C?te de Nacre, Caen, 14033, France|CH René Dubos, Cergy-Pontoise, 95303, France|Centre Hospitalier William Morey, Chalon-sur-Sa?ne, 71100, France|CHU Estaing, Clermont-Ferrand, 63000, France|CHSF Gilles de Corbeil, Corbeil-Essonnes, 91100, France|CHU Henri Mondor, Créteil, 94010, France|CHU Fran?ois Mitterrand, Dijon, 21079, France|CHU de Grenoble, Grenoble cedex 09, 38043, France|Groupe Hospitalier de la Rochelle Ré Aunis, La Rochelle, 17000, France|CH Le Mans, Le Mans cedex 09, 72037, France|Clinique Victor Hugo - Centre Jean Bernard, Le Mans, 72000, France|Centre Hospitalier de Lens, Lens, 62307, France|H?pital Claude Huriez, Lille cedex, 59037, France|H?pital Saint Vincent de Paul, Lille, 59020, France|CHRU de Limoges - H?pital Dupuytren, Limoges, 87042, France|Institut Paoli Calmettes, Marseille, 13273, France|Centre Hospitalier de Meaux, Meaux cedex, 77104, France|CH de Mont de Marsan, Mont-de-Marsan, 40000, France|Clinique Beausoleil, Montpellier, 34000, France|CHRU de Montpellier - Service de Médecine Interne, Montpellier, 34295, France|CHU de Montpellier - Service d'hématologie Oncologie, Montpellier, 34295, France|CHU Nantes - H?tel Dieu, Nantes cedex 1, 44093, France|Centre Catherine de Sienne, Nantes, 44277, France|H?pital Archet 1, Nice cedex 3, 06202, France|Centre Antoine Lacassagne, Nice, 06189, France|CHU de N?mes, N?mes cedex 9, 30029, France|CHR d'Orléans, Orléans, 45067, France|H?pital Saint-Louis, Paris, 75010, France|H?pital Saint Antoine - Service de Médecine Interne, Paris, 75012, France|H?pital de La Pitié-Salpêtrière, Paris, 75013, France|H?pital Saint Antoine - Service d'Hématologie Clinique, Paris, 75571, France|H?pital Cochin, Paris, 75679, France|H?pital Necker, Paris, 75743, France|Centre Hospitalier Joffre, Perpignan, 66 046, France|CHU de Haut-Lévèque, Pessac, 33604, France|Centre Hospitalier Lyon-Sud, Pierre-Bénite, 69495, France|CHU de Poitiers, Poitiers, 86021, France|Centre Hospitalier Annecy Genevois, Pringy, 74374, France|CHU de Reims, Reims, 51092, France|H?pital PONTCHAILLOU, Rennes, 35033, France|Centre Hospitalier de Rochefort, Rochefort, 17301, France|Centrer Hospitalier de Roubaix, Roubaix, 59056, France|Centre Henri Becquerel, Rouen, 76038, France|CH Yves Le Foll, Saint-Brieuc, 22000, France|H?pitaux Universitaires de Strasbourg, Strasbourg, 67091, France|IUCT Oncopole, Toulouse, 31059, France|H?pital Bretonneau, Tours, 37000, France|Centre Hospitalier de Troyes, Troyes, 10003, France|CH Valence, Valence, 26953, France|CHU Brabois, Vandoeuvre-les-Nancy, 54511, France Less <<
NCT06572982 Acute Myeloid Leukemia NOT_YET_RECRUITING 2025-05-26 -
NCT01201811 Myelodysplastic Syndromes PHASE4 COMPLETED 2013-05-01 Changhua Christian Hospital, C... More >>hanghua, 500, Taiwan|Chiayi Chang Gung Memorial Hospital, Chiayi, 613, Taiwan|Buddhist Tzu Chi General Hospital-Hualien Tzu Chi Medical Center, Hualien, 970, Taiwan|Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, 833, Taiwan|Kaohsiung Medical Hospital University, Kaohsiung, 807, Taiwan|Shuang-ho Hospital, New Taipei City, 23561, Taiwan|China Medical University Hospital, Taichung, 404, Taiwan|National Cheng Kung University Hospital, Tainan, 704, Taiwan|National Taiwan University Hospital, Taipei, 10002, Taiwan|Taipei Veterans General Hospital, Taipei, 11217, Taiwan|Tri-Service General Hospital, Taipei, 11490, Taiwan Less <<
NCT01599325 Myelodysplastic Syndrome (MDS) PHASE2 COMPLETED 2018-03-13 Peking University People's Hos... More >>pital, Beijing, 100044, China|The 301 Hospital- Chinese PLA General Hospital, Beijing, 300200, China|The Third Hospital of Peking University, Beijing, China|West China Hospital of Sichuan University, Chengdu, 610041, China|Guangdong General Hospital, Guangzhou, 510080, China|1st Hospital Zhejiang University (The First Affiliated Hospital of Zhejiang University ), Hangzhou, 310003, China|Ruijin Hospital Shanghai Jiaotong University, Shanghai, 200025, China|Shanghai 6th Hospital, Shanghai, 200233, China|The 1st Hospital of Soochow University, Suzhou, 215006, China|Blood Disease Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Tianjin, 300041, China|Wuhan Union Hospital, Wuhan, 430000, China Less <<
NCT00005934 Beta Thalassemia PHASE2 COMPLETED 2025-06-03 National Institute of Diabetes... More >> and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, 20892, United States Less <<
NCT01186939 Myelodysplastic Syndromes PHASE3 COMPLETED 2009-09-01 East Melbourne, Victoria, Aust... More >>ralia|Herston, Australia|Perth, Australia|Woolloongabba, Australia|Plovdiv, Bulgaria|Aulnay Sous Bois Cedex, France|Berlin, Germany|Dusseldorf, Germany|Essen, Germany|Kiel, Germany|Heraklio, Crete, Greece|Haidari, Greece|Budapest, Hungary|Bologna, Italy|Firenze, Italy|Genova, Italy|Rome, Italy|Nijmegen, Netherlands|Lodz, Poland|Avda Campanar, Spain|Leon, Spain|London, United Kingdom Less <<
NCT01652781 Myelodysplastic Syndrome PHASE2 UNKNOWN 2025-12-16 Seoul St. Mary's Hospital, Seo... More >>ul, 137-701, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of Less <<
NCT00384956 Myelodysplastic Syndromes PHASE2 COMPLETED 2025-03-10 Washington University School o... More >>f Medicine, St. Louis, Missouri, 63110, United States Less <<
NCT00569660 Myelofibrosis PHASE2 COMPLETED 2025-04-08 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT00350818 Myelodysplastic Syndrome|Leuke... More >>mia Less << PHASE1 COMPLETED 2025-08-10 UT MD Anderson Cancer Center, ... More >>Houston, Texas, 77030, United States Less <<
NCT00739388 Leukemia PHASE2 COMPLETED 2025-11-12 Kantonspital Aarau, Aarau, CH-... More >>5001, Switzerland|Kantonsspital Baden, Baden, CH-5404, Switzerland|Universitaetsspital-Basel, Basel, CH-4031, Switzerland|Oncology Institute of Southern Switzerland, Bellinzona, CH-6500, Switzerland|Inselspital Bern, Bern, CH-3010, Switzerland|Spitalzentrum Biel, Biel, CH-2500, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, CH-1011, Switzerland|Kantonsspital, Luzerne, Luzerne, CH-6000, Switzerland|Kantonsspital - St. Gallen, St. Gallen, CH-9007, Switzerland|Hopitaux Universitaires de Geneve, Thonex-Geneve, CH-1226, Switzerland|UniversitaetsSpital Zuerich, Zurich, CH-8091, Switzerland Less <<
NCT02447666 Myelodysplastic Syndrome|Leuke... More >>mia, Myelomonocytic, Juvenile Less << PHASE2 COMPLETED 2019-05-24 St. Anna Kinderkrebsforschung,... More >> CHILDREN'S CANCER RESEARCH INSTITUTE, Vienna, 1090, Austria|Hopital Universitaire des Enfants, Brussels, 1020, Belgium|University Hospital Ghent, Ghent, 9000, Belgium|University Hospital Motol, Prague 5, 150 06, Czechia|Rigshospitalet, Copenhagen, DK-2100, Denmark|Centre Hospitalier Universitaire Lyon, Lyon, 69008, France|Hopital d'Enfants de la Timone, Marseille Cedex 01, 13005, France|Hopital Robert Debre, Paris, 75935, France|Klinikum Augsburg, Augsburg, 86156, Germany|Charite Berlin, Berlin, 13353, Germany|Universitaetsklinikum Carl Gustav Carus, Dresden, 01307, Germany|Hematology, Oncology and clinical immunology / Heinrich-Heine-University, Dusseldorf, 40225, Germany|Universitatsklinikum Essen, Essen, 45147, Germany|Klinikum der Johann Wolfgang Goethe-Universit?t Frankfurt/Main, Frankfurt am Main, 60596, Germany|Universitatsklinik, Freiburg, 79106, Germany|University of Hamburg, Hamburg, 20246, Germany|Medizinische Hochschule Hannover, Hannover, 30625, Germany|Universitatsklinikum, Jena, 7740, Germany|Universitatsklinikum Schleswig-Holstein, Kiel, 24105, Germany|Klinikum der Universitaet Muenchen, Munchen, 80336, Germany|Universitatsklinik Munster, Münster, 48149, Germany|Krankenhaus Barmherzige Bruder Regensburg, Regensburg, 93049, Germany|Universitatsklinikum, Tübingen, 72076, Germany|Our Lady's Hospital for Sick Children, Dublin 12, Ireland|Policlinico Sant'Orsola-Malpighi, Bologna, 40138, Italy|IRCCS Gaslini Hospital, Genova Quarto, 16148, Italy|Azienda Ospedaliera San Gerardo, Monza, 20900, Italy|General Hospital, Padova, 35128, Italy|IRCCS Policlinico San Matteo, Pavia, 27100, Italy|Ospedale Bambin Gesu, Roma, 00165, Italy|Regina Margherita Children's Hospital, Torino, 10126, Italy|Erasmus University Medical Center, Rotterdam, 3015 GJ, Netherlands|Hospital Sant Joan de Deu, Barcelona, 8950, Spain|Hospital Infantil Universitario Nino Jesus, Madrid, 28009, Spain|Hospital Universitario Virgen de La Arrixaca, Murcia, 30120, Spain|Queen Silvia Childrens Hospital, Gothenburg, SE-416 85, Sweden|Karolinska University Hospital, Stockholm, SE-171 76, Sweden|Universit?ts-Kinderklinik, Zurich, 8032, Switzerland|Royal Manchester Children's Hospital, Manchester, M13 9WL, United Kingdom Less <<
NCT00412919 Multiple Myeloma PHASE2 TERMINATED 2025-11-08 The Alfred Hospital, Melbourne... More >>, Victoria, 3004, Australia Less <<
NCT00413478 Chronic Lymphocytic Leukemia|L... More >>eukemia Less << PHASE2 TERMINATED 2025-11-14 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT00887068 Leukemia|AML|MDS PHASE3 COMPLETED 2018-08-20 University of Texas MD Anderso... More >>n Cancer Center, Houston, Texas, 77030, United States Less <<
NCT01747499 Leukemia, Myeloid, Acute|Myelo... More >>dysplastic Syndromes|Precursor Cell Lymphoblastic Leukemia-Lymphoma Less << PHASE1|PHASE2 TERMINATED 2018-12-24 Washington University School o... More >>f Medicine, Saint Louis, Missouri, 63110, United States Less <<
NCT01050790 Multiple Myeloma COMPLETED 2025-09-16 Virginia Commonwealth Universi... More >>ty, Richmond, Virginia, 23298, United States Less <<
NCT01338337 Myelodysplastic Syndrome (MDS) PHASE2 COMPLETED 2025-12-15 Hospital General de Jerez, Jer... More >>ez, Cádiz, 11407, Spain|Hospital Costa del Sol, Marbella, Malaga, 29603, Spain|Hospital Reina Sofía, Servicio de Hematología, Cordoba, 14004, Spain|Hospital Universitario San Cecilio, Granada, 18012, Spain|Hospital Virgen de las Nieves, Granada, 18840, Spain|Hospital Juan Ramón Jiménez, Huelva, 21005, Spain|Hospital Carlos Haya, Malaga, 29800, Spain|Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain|Hospital Universitario Virgen de Valme, Sevilla, 41014, Spain Less <<
NCT06598332 Graft-Versus-Host Disease(GVHD... More >>) Less << EARLY_PHASE1 NOT_YET_RECRUITING 2029-02-01 Houston Methodist Hospital, Ho... More >>uston, Texas, 77030, United States|Texas Children's Hospital, Houston, Texas, 77030, United States Less <<
NCT01305460 Myelodysplastic Syndrome PHASE1|PHASE2 COMPLETED 2015-11-16 CHU d'Amiens, Amiens, 80054, F... More >>rance|Centre Hospitalier de La Cote Basque, Bayonne, 64100, France|H?pital Avicenne, Bobigny, 93009, France|Centre henri Mondor, Creteil, 94010, France|CHU Albert Michallon - Service d'Hématologie Clinique, Grenoble, 38043, France|Centre Hospitalier du Mans, Le Mans cedex, 72037, France|H?pital Huriez, Lille, 59037, France|H?pital Paoli Calmettes, Marseille, 13273, France|Centre Hospitalier de Meaux, Meaux, 77100, France|CHU Brabois, Nancy, 54511, France|CHU de nantes, Nantes, 44093, France|H?pital l'Archet de Nice, Nice, 06202, France|H?pital Cochin, Paris, 75004, France|H?pital Saint Louis, Paris, 75010, France|Hopital Saint Louis - AP-HP, Hematology Dpt, Paris, 75475, France|CHU de Haut-Lévèque, Pessac, 33604, France|CHU de Poitiers, Poitiers, 86021, France|CHRU Annecy Hospital, Pringy, 74374, France|H?pital Pontchaillou, Rennes, 35033, France|Hopital Purpan Service d'Hématologie Clinique, Toulouse, 31059, France|CH de Valence, Valence, 26953, France Less <<
NCT04891068 Breast Cancer Female|Breast Ca... More >>ncer Invasive Less << PHASE2 RECRUITING 2025-05-26 University of Illinois Cancer ... More >>Center, Chicago, Illinois, 60612, United States Less <<
NCT02940483 Brain Tumor Recurrent EARLY_PHASE1 COMPLETED 2018-11-28 UTHealth & Children's Memorial... More >> Hermann Hospital, Houston, Texas, 77030, United States Less <<
NCT00387647 Leukemia PHASE2 COMPLETED 2025-08-14 H. Lee Moffitt Cancer Center a... More >>nd Research Institute, Tampa, Florida, 33612, United States|Duke University Medical Center, Durham, North Carolina, 27710, United States Less <<
NCT03666559 Recurrent IDH1/2 Mutated Gliom... More >>a Less << PHASE2 ACTIVE_NOT_RECRUITING 2024-03-23 Pitie Salpetriere Hospital, Pa... More >>ris, 75013, France Less <<
NCT00446303 Leukemia, Myelocytic, Acute|My... More >>elodysplastic Syndromes Less << PHASE2 TERMINATED 2025-07-10 CHU d'Amiens, Amiens, 80054, F... More >>rance|CHU Angers, Angers, 49033, France|CH d'Avignon, Avignon, 84000, France|CHU de Caen, Caen, 14033, France|Hopital d'Instruction des Armées Percy, Clamart, 92140, France|Hopital Henri Mondor, Creteil, 94000, France|CHU de Dijon, Dijon, 21034, France|CHU Albert Michallon, Grenoble, 38043, France|CHRU Hurriez, Lille, 59057, France|CHRU de Limoges, Limoges, 87046, France|Hopital Edouard Herriot, Lyon, 69437, France|Hopital Paoli Calmette, Marseille, 13273, France|Hopital Hotel Dieu, Nantes, 44093, France|Hopital Archet, Nice, 06202, France|Hopital Saint Louis, Paris, 75475, France|Hopital Saint Antoine, Paris, 75571, France|Hopital Cochin, Paris, 75679, France|Hopital Haut Leveque, Pessac, 33604, France|Hopital Jean-Bernard, Poitiers, 86021, France|CHRU de Reims, Reims, 51092, France|CHU Pontchaillou, Rennes, 35033, France|Hopital Hautepierre, Strasbourg, 67098, France|Hopital Purpan, Toulouse, 31031, France|CHU Brabois, Vandoeuvre, 54511, France|CH Versailles, Versailles, 78000, France Less <<
NCT00481273 Myelodysplastic Syndromes COMPLETED 2010-08-31 AVIDA Registry Help, Kansas Ci... More >>ty, Missouri, 66210, United States Less <<
NCT01462578 Acute Myelocytic Leukemia|Myel... More >>odysplastic Syndrome Less << PHASE2 COMPLETED 2025-02-21 Charité Campus Benjamin Frankl... More >>in, Berlin, Germany|Universit?tsklinikum Bonn, Bonn, Germany|Klinikum Chemnitz (Küchwald), Chemnitz, Germany|Universit?tsklinikum Carl Gustav Carus, Medizinische Klinik und Poliklinik I, Dresden, Germany|Universit?tsklinikum Essen, Klinik für H?matologie (Westdeutsches Tumorzentrum), Essen, Germany|Klinikum der J. W. Goethe-Universit?t, Medizinische Klinik II H?matologie / Onkologie, Frankfurt am Main, Germany|Universit?tsklinikum Freiburg, Freiburg, Germany|Universit?tsklinikum Heidelberg, Medizinische Klinik, Abt. Innere Medizin V, Heidelberg, Germany|Klinikum rechts der Isar der TU München, III. Med. Klinik und Poliklinik, München, Germany|LMU München, Klinikum Gro?hadern, Med. Klinik III, München, Germany|Universit?tsklinikum Münster, Innere Medizin A - KMT-Zentrum, Münster, Germany Less <<
NCT00728520 Acute Myeloid Leukemia|Elderly PHASE2 UNKNOWN 2025-06-12 Kansas City Veterans Affairs M... More >>edical Center, Kansas City, Missouri, 64218, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.09mL

0.82mL

0.41mL

20.47mL

4.09mL

2.05mL

40.95mL

8.19mL

4.09mL

References

[1]Christman JK. 5-Azacytidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002 Aug 12;21(35):5483-95.

[2]Creusot F, Acs G, et al. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. J Biol Chem. 1982 Feb 25;257(4):2041-8.

[3]Mahesh S, Saxena A, et al. Intratracheally administered 5-azacytidine is effective against orthotopic human lung cancer xenograft models and devoid of important systemic toxicity. Clin Lung Cancer. 2010;11(6):405-11.

[4]Heby O, Russell DH. Depression of polyamine synthesis in L1210 leukemic mice during treatment with a potent antileukemic agent, 5-azacytidine. Cancer Res. 1973;33(1):159-65.

[5]Holliday R, Pugh JE. DNA modification mechanisms and gene activity during development. Science. 1975 Jan 24;187(4173):226-32.

[6]Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC. 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007 Jun;6(6):1718-27.

[7]Harman RM, Curtis TM, Argyle DJ, Coonrod SA, Van de Walle GR. A Comparative Study on the In Vitro Effects of the DNA Methyltransferase Inhibitor 5-Azacytidine (5-AzaC) in Breast/Mammary Cancer of Different Mammalian Species. J Mammary Gland Biol Neoplasia. 2016 Jun;21(1-2):51-66.

[8]Cao D, Li D, Huang Y, Ma Y, Zhang B, Zhao C, Deng S, Luo M, Yin T, Wei YQ, Wang W. 5-Azacytidine promotes invadopodia formation and tumor metastasis through the upregulation of PI3K in ovarian cancer cells. Oncotarget. 2017 Jun 20;8(36):60173-60187.

[9]Griffin PT, Niederhuth CE, Schmitz RJ. A Comparative Analysis of 5-Azacytidine- and Zebularine-Induced DNA Demethylation. G3 (Bethesda). 2016 Sep 8;6(9):2773-80.

 

Historical Records

Categories